Cargando…
Erratum for Mesplède et al., “The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration”
Autores principales: | Mesplède, Thibault, Leng, Jing, Pham, Hanh Thi, Liang, Jiaming, Quan, Yudong, Han, Yingshan, Wainberg, Mark A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156196/ https://www.ncbi.nlm.nih.gov/pubmed/30254122 http://dx.doi.org/10.1128/mBio.01450-18 |
Ejemplares similares
-
The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration
por: Mesplède, Thibault, et al.
Publicado: (2017) -
The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound
por: Wainberg, Mark, et al.
Publicado: (2014) -
The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness
por: Wares, Melissa, et al.
Publicado: (2014) -
Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
por: Mesplède, Thibault, et al.
Publicado: (2014) -
Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy
por: Wainberg, Mark A, et al.
Publicado: (2015)